X

ABL Biotechnologies Ltd. Stock Analysis

Small Cap
Evaluated by 132 users | BSE: 526955 | NSE: |
Pharmaceuticals & Drugs
ABL Biotechnologies incorporated in 1992, is a pioneer in harnessing the biodiversity of the Indian marine environment. ABL is engagaed in identification and commercial extraction of bio-chemicals, predominantly from microbes, that are used as nutritional, cosmetic, pharmaceutical, and...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12
Return on Capital Employed -3.53%2.84%12.07%24.89%15.76%10.53%-0.41%-43.69%-1.67%-0.5%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 0.22.65.879.316.98.22.200
Y-o-Y Gr. Rt.-1400%127.5%20.9%32.2%81.9%-51.7%-72.8%-98.2%-100%
Adjusted EPS (Rs.) -0.350.241.024.15.264.37-1.17-25.17-0.73-0.22
Y-o-Y Gr. Rt.-NA325%302%28.3%-16.9%-126.8%NANANA
Book Value per Share (Rs.) 5.615.486.169.0216.5720.4443.2618.4417.7717.61
Adjusted Net Profit -0.10.10.41.72.21.8-1-20.6-0.6-0.2
Net Op. Cash Flow (Rs. Cr.) 00.60.6-3.61.8-1.70.8-9.6-0.5-0.1
Debt to Cash Flow from Ops 78.481.792.75-1.435.66-8.621.33-1.74-36.16-148.86
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
ABL Biotechnologies Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -100%-100%-100%-100%
Adjusted EPS NA-153%NANA
Book Value per Share 13.61.2-25.9-0.9
Share Price -19.6% -8.6% - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12
Return on Equity (%) -5.223.6713.6540.0124.5714.27-3.62-69.32-3.15-0.96
Operating Profit Margin (%) -114.037.6911.4417.7418.5819.174.9-899.17-1266.040
Net Profit Margin (%) -83.623.887.1823.9723.2510.63-11.73-927.82-1424.990
Debt to Equity 0.550.470.61.41.491.690.471.11.161.18
Working Capital Days 31068691822642536461,61374,6620
Cash Conversion Cycle -179-79-71-51-39-19-34-21-9,3560
Entity Percentage Holding
Promoters 0.60%
Institutions 10.89%
Non-Institutions 88.51%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of ABL Biotechnologies's performance infers:

ABL Biotechnologies earnings have declined by -153%, whereas share price has depreciated -8.6% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of ABL Biotechnologies share prices over the last 10 years. Here is what we found out:

ABL Biotechnologies share price has depreciated -27.4% annually over the past ten years.

ABL Biotechnologies incorporated in 1992, is a pioneer in harnessing the biodiversity of the Indian marine environment. ABL is engagaed in identification and commercial extraction of bio-chemicals, predominantly from microbes, that are used as nutritional, cosmetic, pharmaceutical, and industrial intermediates.

Company’s R&D unit is located at Vishakapatnam that has been recognised by the Department of Scientific and Industrial Research, Ministry of Science and Technology,

ABL Biotechnologies incorporated in 1992, is a pioneer in harnessing the biodiversity of the Indian marine environment. ABL is engagaed in identification and commercial extraction of bio-chemicals, predominantly from microbes, that are used as nutritional, cosmetic, pharmaceutical, and industrial intermediates.

Company’s R&D unit is located at Vishakapatnam that has been recognised by the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India.

Company’s microbial metabolites laboratory located at Chennai is focused on evaluating new sources of biochemicals from marine organisms.

Company has collaborated with institutions such as the National Facility for Marine Cyanobacteria, Bharathidasan University, Trichy, the National Institute of Oceanography, The Madras University and the Dr.A.L.M Post Graduate Institute of Medical Sciences, Madras to introduce joint development programmes of advanced research in India.

Company has taken various initiatives such as sale or licensing of technologies, development of biochemical intermediates, conducting research on aquatic biotechnology, product development for therapeutics industry and undertaking contract research. Under contract research company manufactures finished formulations in various formats including soft and hard gelatine capsules, tablets, liquid orals and topical ointments, for various disease states.

ABL has been conducting research on polysaccharides, essential fatty acids, natural pigments, tracers and tags with considerable success. Presently company is focus on developing pharmaceuticals products catering various areas like anti-bacterials and anti-virals, enzymes, bio-molecular materials, bio-monitors and diagnostics, bio-pesticides, bioremediation and aquaculture.

Product portfolio

Company manufactures Beta carotene, which is used as a source of Vitamin A for protection against strokes and cataracts, enhancing the immune system, and preventing photo sensitivity disorders.ABL manufactures Lycopene, an antioxidant carotenoid and pigment that gives characteristic red colour to tomatoes, watermelon, and pink grapefruit.Company developed Lutein, a carotenoid found in fruits and vegetables, including dark green and leafy vegetables, such as spinach and kale, as well as in foods comprising corn and egg yolks.ABL Biotechnologies involves in the production of carotenoid fortified products, including jams, squashes, ketchups and sauces, cooking oils, and chocolates.

Future Plan

ABL Biotechnologies R&D unit plans to strengthen its product portfolio by developing new molecules.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback